Drug Trial Radar · NCT04172831
A Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With Fibromyalgia
Last checked: Nov 20, 2026Latest source record: Aug 8, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
503
Actual
Start
Dec 9, 2019
Primary completion
Oct 29, 2020
Study completion Oct 29, 2020
Sponsor
- Lead sponsor
- Tonix Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 21, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 3, randomized, parallel-group, double-blind, placebo-controlled, 14-week study designed to evaluate the efficacy and safety of TNX-102 SL 5.6 mg (2 x 2.8 mg tablets) taken daily at bedtime for the treatment of fibromyalgia.
Conditions
- Fibromyalgia
Interventions
TNX-102 SLDrug
Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patients will have the dose increased to 2 tablets for 12 weeks.
Placebo SL TabletDrug
Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patients will have the dose increased to 2 tablets for 12 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline to Week 14 in the Numerical Rating Scale (NRS) Weekly Average of Daily Self-reported Average Pain Severity Scores.Time frame: 14 weeks
Locations
39 sites in 1 country. Site status is shown where the registry gives one.
Tonix Clinical Site
Birmingham, Alabama
Tonix Clinical Site
Phoenix, Arizona
Tonix Clinical Site
Oceanside, California
Tonix Clinical Site
Sacramento, California
Tonix Clinical Site
San Diego, California
Tonix Clinical Site
Temecula, California
Tonix Clinical Site
Cromwell, Connecticut
Tonix Clinical Site
Fort Myers, Florida
Tonix Clinical Site
Jacksonville, Florida
Tonix Clinical Site
North Miami, Florida
Tonix Clinical Site
Ocala, Florida
Tonix Clinical Site
Orlando, Florida
Tonix Clinical Site
Atlanta, Georgia
Tonix Clinical Site
Evansville, Indiana
Tonix Clinical Site
West Des Moines, Iowa
Tonix Clinical Site
Prairie Village, Kansas
Tonix Clinical Site
New Orleans, Louisiana
Tonix Clinical Site
Boston, Massachusetts
Tonix Clinical Site
North Dartmouth, Massachusetts
Tonix Clinical Site
Las Vegas, Nevada
Tonix Clinical Site
Williamsville, New York
Tonix Clinical Site
High Point, North Carolina
Tonix Clinical Site
Raleigh, North Carolina
Tonix Clinical Site
Fargo, North Dakota
Tonix Clinical Site
Cincinnati, Ohio
Tonix Clinical Site
Dayton, Ohio
Tonix Clinical Site
North Canton, Ohio
Tonix Clinical Site
Oklahoma City, Oklahoma
Tonix Clinical Site
Tulsa, Oklahoma
Tonix Clinical Site
Portland, Oregon
Tonix Clinical Site
Allentown, Pennsylvania
Tonix Clinical Site
Warwick, Rhode Island
Tonix Clinical Site
Chattanooga, Tennessee
Tonix Clinical Site
Memphis, Tennessee
Tonix Clinical Site
Austin, Texas
Tonix Clinical Site
Dallas, Texas
Tonix Clinical Site
Salt Lake City, Utah
Tonix Clinical Site
Charlottesville, Virginia
Tonix Clinical Site
Kenosha, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.